Francisco J. Garcia-Ballina

Oviedo, AS 33011, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease.

GlycA Levels during the Earliest Stages of Rheumatoid Arthritis: Potential Use as a Biomarker of Subclinical Cardiovascular Disease.

Journal: Journal of clinical medicine

Published: June 22, 2020

Profiling of Serum Oxylipins During the Earliest Stages of Rheumatoid Arthritis.

Profiling of Serum Oxylipins During the Earliest Stages of Rheumatoid Arthritis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: May 05, 2020

Vitamin D Receptor Polymorphism and DHCR7 Contribute to the Abnormal Interplay Between Vitamin D and Lipid Profile in Rheumatoid Arthritis.

Vitamin D Receptor Polymorphism and DHCR7 Contribute to the Abnormal Interplay Between Vitamin D and Lipid Profile in Rheumatoid Arthritis.

Journal: Scientific reports

Published: October 09, 2018

IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis.

IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis.

Journal: Frontiers in immunology

Published: September 10, 2018

Profiling of B-Cell Factors and Their Decoy Receptors in Rheumatoid Arthritis: Association With Clinical Features and Treatment Outcomes.

Profiling of B-Cell Factors and Their Decoy Receptors in Rheumatoid Arthritis: Association With Clinical Features and Treatment Outcomes.

Journal: Frontiers in immunology

Published: June 22, 2018

Biological Dose Tapering in Daily Clinical Practice: A 10 Year Follow-up Study.

Biological Dose Tapering in Daily Clinical Practice: A 10 Year Follow-up Study.

Journal: Reumatologia clinica

Published: June 04, 2018

Heterogeneity of the Type I Interferon Signature in Rheumatoid Arthritis: A Potential Limitation for Its Use As a Clinical Biomarker.

Heterogeneity of the Type I Interferon Signature in Rheumatoid Arthritis: A Potential Limitation for Its Use As a Clinical Biomarker.

Journal: Frontiers in immunology

Published: November 23, 2017

High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: A potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein.

High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: A potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein.

Journal: Journal of clinical lipidology

Published: March 13, 2017

Anti-MDA5 dermatomyositis mimicking psoriatic arthritis.

Anti-MDA5 dermatomyositis mimicking psoriatic arthritis.

Journal: Reumatologia clinica

Published: September 05, 2016

Antibodies to paraoxonase 1 are associated with oxidant status and endothelial activation in rheumatoid arthritis.

Antibodies to paraoxonase 1 are associated with oxidant status and endothelial activation in rheumatoid arthritis.

Journal: Clinical science (London, England : 1979)

Published: May 27, 2016

Non-Esterified Fatty Acids Profiling in Rheumatoid Arthritis: Associations with Clinical Features and Th1 Response.

Non-Esterified Fatty Acids Profiling in Rheumatoid Arthritis: Associations with Clinical Features and Th1 Response.

Journal: PloS one

Published: May 03, 2016

Paraoxonase 1 Activity Is Modulated by the rs662 Polymorphism and IgG Anti-High-Density Lipoprotein Antibodies in Patients With Rheumatoid Arthritis: Potential Implications for Cardiovascular Disease.

Paraoxonase 1 Activity Is Modulated by the rs662 Polymorphism and IgG Anti-High-Density Lipoprotein Antibodies in Patients With Rheumatoid Arthritis: Potential Implications for Cardiovascular Disease.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: November 03, 2015

Showing 1-12 of 24

Last Updated: 09/26/2026